SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Epiroc AB (publ) (EPOKY) trades at a trailing P/E of 3.1, forward P/E of 2.7. Trailing earnings yield is 32.68%, forward earnings yield 37.31%. PEG 0.19 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
- VALUE (100/100, Pass) — P/E is below market average (3.1); PEG ≤ 1.0 — Peter Lynch undervalued (0.19); earnings yield beats bond yields (32.68%).
- Forward P/E 2.7 (down from trailing 3.1) — analysts expect earnings to grow, which would improve the valuation.
- PEG Ratio 0.19 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Trailing Earnings Yield 32.68% — exceeds typical bond yields (~4.3%), making equity attractive vs fixed income. Forward yield improves to 37.31% as earnings recover.
Overall SharesGrow Score: 73/100 with 4/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
100/100
Price-to-Earnings & upside
Proven by this page
✓
HEALTH
100/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — EPOKY
Valuation Multiples
P/E (TTM)3.1
Forward P/E2.7
PEG Ratio0.19
Forward PEG0.19
P/B Ratio0.00
P/S Ratio0.42
EV/EBITDA0.0
Per Share Data
EPS (TTM)$7.23
Forward EPS (Est.)$8.25
Book Value / Share$0.00
Revenue / Share$52.67
FCF / Share$0.00
Yields & Fair Value
Earnings Yield32.68%
Forward Earnings Yield37.31%
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2015 |
$2.95 |
$28.66B |
$3.58B |
12.5% |
| 2016 |
$2.67 |
$27.1B |
$3.24B |
11.9% |
| 2017 |
$3.55 |
$31.44B |
$4.3B |
13.7% |
| 2018 |
$4.50 |
$38.29B |
$5.43B |
14.2% |
| 2019 |
$4.89 |
$40.85B |
$5.87B |
14.4% |
| 2020 |
$4.48 |
$36.12B |
$5.4B |
14.9% |
| 2021 |
$5.84 |
$39.65B |
$7.06B |
17.8% |
| 2022 |
$6.95 |
$49.69B |
$8.4B |
16.9% |
| 2023 |
$7.81 |
$60.34B |
$9.43B |
15.6% |
| 2024 |
$7.23 |
$63.6B |
$8.73B |
13.7% |
